Kiniksa Pharmaceuticals (KNSA) Financials

$20.21 -0.32 (-1.56%)

Closing price 04:00 PM Eastern

Extended Trading

$20.21 0.00 (0.00%)

As of 06:15 PM Eastern

Annual Income Statements for Kiniksa Pharmaceuticals

This table shows Kiniksa Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-65	-103	-162	-161	-158	183	14	-43
Consolidated Net Income / (Loss)	-65	-103	-162	-161	-158	183	14	-43
Net Income / (Loss) Continuing Operations	-65	-103	-162	-161	-158	183	14	-43
Total Pre-Tax Income	-65	-103	-164	-156	-157	11	-17	-36
Total Operating Income	-65	-108	-170	-157	-157	9.77	-25	-46
Total Gross Profit	0.00	0.00	0.00	0.00	29	173	180	234
Total Revenue	0.00	0.00	0.00	0.00	39	220	270	423
Operating Revenue	-	-	0.00	0.00	39	220	270	423
Total Cost of Revenue	0.00	0.00	0.00	0.00	9.94	47	90	189
Operating Cost of Revenue	-	-	0.00	0.00	9.94	47	90	189
Total Operating Expenses	65	108	170	157	185	163	206	280
Selling, General & Admin Expense	9.04	22	35	45	86	98	129	168
Research & Development Expense	56	87	135	112	99	65	76	112
Total Other Income / (Expense), net	0.53	4.72	6.05	1.13	0.10	1.25	8.54	9.46
Other Income / (Expense), net	-	-	-	1.13	0.10	1.25	8.54	9.46
Income Tax Expense	0.00	-0.21	-2.05	5.15	1.39	-172	-31	7.04
Basic Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	($2.30)	$2.64	$0.20	($0.60)
Weighted Average Basic Shares Outstanding	1.81M	29.55M	54.05M	61.84M	68.58M	69.38M	70.06M	71.42M
Diluted Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	($2.30)	$2.60	$0.20	($0.60)
Weighted Average Diluted Shares Outstanding	1.81M	29.55M	54.05M	61.84M	68.58M	70.42M	71.92M	71.42M
Weighted Average Basic & Diluted Shares Outstanding	1.81M	29.55M	54.05M	61.84M	138.21M	139.51M	141.23M	145.29M

This table shows Kiniksa Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	224	4.46	-12	15	-14	25	-18	-3.99	-13	-8.90
Consolidated Net Income / (Loss)	224	4.46	-12	15	-14	25	-18	-3.91	-13	-8.89
Net Income / (Loss) Continuing Operations	224	4.46	-12	15	-14	25	-18	-3.91	-13	-8.89
Total Pre-Tax Income	47	6.84	-9.36	-1.24	-8.50	2.45	-14	2.30	-7.20	-17
Total Operating Income	46	6.05	-11	-3.15	-11	0.08	-17	-0.12	-9.66	-19
Total Gross Profit	88	48	33	50	41	57	48	66	63	56
Total Revenue	99	62	48	71	67	83	80	109	112	123
Operating Revenue	99	62	48	71	67	83	80	109	112	123
Total Cost of Revenue	12	14	15	22	26	27	31	42	49	66
Operating Cost of Revenue	12	14	15	22	26	27	31	42	49	66
Total Operating Expenses	41	42	44	53	52	57	65	66	72	76
Selling, General & Admin Expense	25	27	29	29	34	37	39	42	46	41
Research & Development Expense	16	14	15	24	17	20	26	24	26	35
Total Other Income / (Expense), net	0.32	0.79	1.83	1.92	2.43	2.37	2.27	2.42	2.46	2.32
Other Income / (Expense), net	0.32	0.79	1.83	1.92	2.43	2.37	2.27	2.42	2.46	2.32
Income Tax Expense	-177	2.38	2.91	-16	5.36	-23	3.43	6.21	5.49	-8.09
Basic Earnings per Share	$3.23	$0.06	($0.18)	$0.21	($0.20)	$0.37	($0.25)	($0.06)	($0.18)	($0.11)
Weighted Average Basic Shares Outstanding	69.45M	69.38M	69.75M	69.92M	70.19M	70.06M	70.63M	71.00M	71.73M	71.42M
Diluted Earnings per Share	$3.18	$0.07	($0.18)	$0.21	($0.20)	$0.37	($0.25)	($0.06)	($0.18)	($0.11)
Weighted Average Diluted Shares Outstanding	70.55M	70.42M	69.75M	71.63M	70.19M	71.92M	70.63M	71.00M	71.73M	71.42M
Weighted Average Basic & Diluted Shares Outstanding	139.06M	139.51M	139.80M	140.33M	140.68M	141.23M	141.88M	142.49M	144.40M	145.29M

This table details how cash moves in and out of Kiniksa Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-10	27	-25	67	8.22	0.25	-15	76
Net Cash From Operating Activities	-50	-81	-158	-137	-126	5.81	13	26
Net Cash From Continuing Operating Activities	-50	-81	-158	-137	-126	5.81	13	26
Net Income / (Loss) Continuing Operations	-65	-103	-162	-161	-158	183	14	-43
Consolidated Net Income / (Loss)	-65	-103	-162	-161	-158	183	14	-43
Depreciation Expense	0.03	0.29	2.07	2.41	2.36	2.40	2.34	1.70
Amortization Expense	0.00	-1.42	-3.50	0.12	0.66	-0.08	-1.07	0.44
Non-Cash Adjustments To Reconcile Net Income	0.90	6.00	24	21	25	18	-6.67	38
Changes in Operating Assets and Liabilities, net	14	17	-19	1.75	3.24	-197	4.61	29
Net Cash From Investing Activities	-0.07	-239	49	-23	129	-8.08	-30	38
Net Cash From Continuing Investing Activities	-0.07	-239	49	-23	129	-8.08	-30	38
Purchase of Property, Plant & Equipment	-0.07	-5.29	-3.20	-0.28	-0.42	-0.11	-0.13	-0.28
Purchase of Investments	0.00	-402	-489	-430	-157	-136	-205	-202
Sale of Property, Plant & Equipment	-	-	-	0.00	0.00	0.09	0.00	0.03
Sale and/or Maturity of Investments	0.00	168	541	407	306	128	176	240
Net Cash From Financing Activities	40	347	84	227	5.89	2.52	1.50	12
Net Cash From Continuing Financing Activities	40	347	84	227	5.89	2.52	1.50	12
Issuance of Common Equity	0.00	159	84	228	5.89	3.42	3.70	17
Other Financing Activities, net	0.00	0.38	-	0.00	0.00	-0.90	-2.21	-4.98
Cash Income Taxes Paid	0.29	0.38	1.72	0.48	1.28	11	5.61	2.00

This table details how cash moves in and out of Kiniksa Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	81	-53	-42	32	5.26	-9.87	33	-42	-1.90	86
Net Cash From Operating Activities	62	-12	-4.27	-3.74	17	4.33	3.99	5.17	-2.24	19
Net Cash From Continuing Operating Activities	62	-12	-4.27	-3.74	17	4.33	3.99	5.19	-2.26	19
Net Income / (Loss) Continuing Operations	224	4.46	-12	15	-14	25	-18	-3.91	-13	-8.89
Consolidated Net Income / (Loss)	224	4.46	-12	15	-14	25	-18	-3.91	-13	-8.89
Depreciation Expense	0.49	0.60	0.60	0.60	0.60	0.54	0.47	0.43	0.40	0.40
Amortization Expense	-0.12	-0.20	-1.06	-1.15	1.44	-0.30	0.30	-0.19	-0.49	0.82
Non-Cash Adjustments To Reconcile Net Income	6.02	-1.28	14	6.42	6.75	-34	6.70	22	-7.26	16
Changes in Operating Assets and Liabilities, net	-168	-15	-5.33	-25	22	12	14	-13	18	10
Net Cash From Investing Activities	19	-43	-38	36	-12	-15	26	-47	-6.35	65
Net Cash From Continuing Investing Activities	19	-43	-38	36	-12	-15	26	-47	-6.35	65
Purchase of Property, Plant & Equipment	-0.02	0.03	-0.02	-0.03	-0.02	-0.06	-0.08	-	-	-0.19
Purchase of Investments	-17	-63	-53	-38	-53	-61	-36	-89	-54	-22
Sale and/or Maturity of Investments	36	20	15	74	41	46	62	42	48	87
Net Cash From Financing Activities	0.36	1.19	0.09	0.16	0.55	0.70	3.61	-0.18	6.69	2.14
Net Cash From Continuing Financing Activities	0.36	1.19	0.09	0.16	0.55	0.70	3.61	-0.18	6.69	2.14
Issuance of Common Equity	0.57	1.29	0.51	0.58	1.66	0.96	3.99	1.14	9.40	2.72
Other Financing Activities, net	-0.21	-0.10	-0.42	-0.42	-1.11	-0.26	-0.38	-1.31	-2.71	-0.58
Cash Income Taxes Paid	1.32	6.08	3.20	3.52	0.20	-1.31	0.00	1.51	-0.77	1.26

This table presents Kiniksa Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	47	322	255	349	233	460	526	581
Total Current Assets	47	314	242	333	196	243	276	332
Cash & Equivalents	46	72	47	114	122	123	108	184
Short-Term Investments	0.00	235	186	209	60	68	98	60
Accounts Receivable	-	-	-	0.00	3.99	13	21	42
Inventories, net	-	-	-	0.00	3.68	22	31	26
Prepaid Expenses	1.44	6.45	8.25	9.56	6.59	11	18	20
Other Current Assets	-	-	-	-	0.00	7.66	0.00	0.00
Plant, Property, & Equipment, net	0.13	6.36	6.40	4.05	2.83	1.66	0.73	0.66
Total Noncurrent Assets	0.26	1.86	6.51	12	34	215	249	248
Intangible Assets	-	-	-	0.00	19	18	17	16
Noncurrent Deferred & Refundable Income Taxes	0.24	1.22	4.37	0.01	0.00	185	219	211
Other Noncurrent Operating Assets	0.03	0.64	2.14	12	14	11	13	21
Total Liabilities & Shareholders' Equity	47	322	255	349	233	460	526	581
Total Liabilities	17	43	29	38	48	64	87	142
Total Current Liabilities	17	43	28	32	45	47	64	101
Accounts Payable	1.22	11	5.69	0.50	1.87	7.90	8.25	2.04
Accrued Expenses	16	31	20	29	38	30	45	81
Current Deferred Revenue	-	-	-	-	-	0.00	0.31	0.00
Other Current Liabilities	0.00	0.22	1.72	2.14	4.93	9.06	10	18
Total Noncurrent Liabilities	0.00	0.14	1.28	5.68	2.94	16	24	41
Noncurrent Deferred Revenue	-	-	-	-	0.00	12	12	32
Other Noncurrent Operating Liabilities	-	0.14	1.28	5.68	2.94	4.46	12	9.69
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-90	279	225	312	185	396	439	438
Total Preferred & Common Equity	-90	279	225	312	185	396	439	438
Total Common Equity	-90	279	225	312	185	396	439	438
Common Stock	1.29	473	581	829	861	888	917	960
Retained Earnings	-91	-194	-356	-517	-675	-492	-478	-521
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.00	0.03	-0.03	-0.07	0.04	0.01	-0.16

This table presents Kiniksa Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	460	443	484	483	520	542	555
Total Current Assets	242	232	246	256	271	301	311
Cash & Equivalents	176	81	113	118	141	99	97
Short-Term Investments	25	107	72	83	72	119	126
Accounts Receivable	11	7.42	25	3.04	16	20	25
Inventories, net	15	23	24	26	27	35	29
Prepaid Expenses	15	13	12	26	14	27	34
Plant, Property, & Equipment, net	2.00	1.39	1.14	0.92	0.71	0.63	0.56
Total Noncurrent Assets	216	210	237	226	248	241	243
Intangible Assets	19	18	18	18	17	17	17
Noncurrent Deferred & Refundable Income Taxes	186	184	204	194	215	204	208
Other Noncurrent Operating Assets	12	7.55	16	15	16	20	19
Total Liabilities & Shareholders' Equity	460	443	484	483	520	542	555
Total Liabilities	76	53	73	78	88	107	118
Total Current Liabilities	56	37	47	53	64	84	96
Accounts Payable	1.47	1.39	0.65	1.01	5.63	7.39	8.33
Accrued Expenses	31	21	35	41	45	63	70
Current Deferred Revenue	12	6.50	4.67	2.56	0.16	0.01	0.00
Other Current Liabilities	12	7.82	6.83	8.74	14	14	18
Total Noncurrent Liabilities	19	16	25	24	24	23	22
Noncurrent Deferred Revenue	14	12	12	12	12	12	12
Other Noncurrent Operating Liabilities	5.26	4.02	13	13	12	11	11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	384	390	412	405	432	435	437
Total Preferred & Common Equity	384	390	412	405	432	435	437
Total Common Equity	384	390	412	405	432	435	437
Common Stock	881	894	901	908	928	935	949
Retained Earnings	-496	-504	-489	-503	-496	-500	-512
Accumulated Other Comprehensive Income / (Loss)	-0.07	0.06	0.01	-0.00	-0.05	-0.13	-0.04

This table displays calculated financial ratios and metrics derived from Kiniksa Pharmaceuticals' official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	471.24%	22.74%	56.61%
EBITDA Growth	0.00%	-67.19%	-56.82%	10.32%	0.12%	108.69%	-215.23%	-121.18%
EBIT Growth	0.00%	-65.38%	-57.14%	8.08%	-0.20%	107.04%	-251.02%	-117.10%
NOPAT Growth	0.00%	-65.38%	-57.14%	7.41%	0.46%	248.23%	-110.85%	-81.04%
Net Income Growth	0.00%	-59.12%	-56.81%	0.30%	2.14%	216.11%	-92.32%	-406.68%
EPS Growth	0.00%	90.27%	14.33%	12.71%	11.88%	213.04%	-92.31%	-400.00%
Operating Cash Flow Growth	0.00%	-61.32%	-95.49%	13.79%	7.50%	104.60%	129.05%	93.14%
Free Cash Flow Firm Growth	0.00%	0.00%	-119.77%	23.52%	-16.82%	67.66%	-10.91%	112.85%
Invested Capital Growth	0.00%	-79.75%	71.62%	-47.76%	124.12%	7,147.57%	13.10%	-16.20%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	94.68%	24.37%	8.65%	10.19%
EBITDA Q/Q Growth	0.00%	0.00%	6.63%	-13.57%	9.78%	144.83%	-41.96%	-118.58%
EBIT Q/Q Growth	0.00%	0.00%	6.36%	-14.00%	9.73%	134.03%	-35.81%	-116.18%
NOPAT Q/Q Growth	0.00%	0.00%	6.36%	-14.82%	9.67%	816.49%	-31.02%	-73.87%
Net Income Q/Q Growth	0.00%	0.00%	6.25%	-15.67%	9.89%	28.61%	310.46%	-376.32%
EPS Q/Q Growth	0.00%	0.00%	-239.72%	-11.54%	11.20%	30.00%	300.00%	-400.00%
Operating Cash Flow Q/Q Growth	0.00%	-5.55%	2.14%	-14.24%	15.01%	486.88%	611.58%	128.47%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-9.78%	11.97%	79.08%	-30.23%	120.79%
Invested Capital Q/Q Growth	0.00%	0.00%	-16.43%	-99.75%	-79.55%	12.14%	13.93%	-8.64%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	74.22%	78.67%	66.72%	55.29%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	-398.30%	6.06%	-5.69%	-8.04%
Operating Margin	0.00%	0.00%	0.00%	0.00%	-406.38%	4.44%	-9.32%	-10.78%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	-406.13%	5.01%	-6.16%	-8.54%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	-409.72%	83.28%	5.21%	-10.21%
Tax Burden Percent	100.00%	99.79%	98.75%	103.30%	100.88%	1,663.01%	-84.58%	119.48%
Interest Burden Percent	99.19%	95.64%	96.44%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	-1,563.01%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	155.99%	-8.05%	-14.95%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	144.81%	-24.03%	-9.94%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	-92.89%	11.43%	5.10%
Return on Equity (ROE)	-215.80%	-66.74%	-64.15%	-60.06%	-63.55%	63.10%	3.37%	-9.85%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-4,380.75%	-38.56%	-20.35%	2.68%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	-53.77%	3.18%	-3.38%	-6.53%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	-54.24%	52.96%	2.86%	-7.80%
Return on Common Equity (ROCE)	643.96%	-40.90%	-64.15%	-60.06%	-63.55%	63.10%	3.37%	-9.85%
Return on Equity Simple (ROE_SIMPLE)	72.32%	-36.96%	-71.81%	-51.74%	-85.35%	46.29%	3.21%	-9.85%
Net Operating Profit after Tax (NOPAT)	-46	-76	-119	-110	-110	163	-18	-32
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-284.47%	73.81%	-6.53%	-7.54%
Net Nonoperating Expense Percent (NNEP)	-41.82%	-15.59%	-15.87%	-18.39%	-19.09%	11.18%	15.98%	-5.01%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	41.03%	-4.02%	-7.28%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	25.78%	21.33%	33.28%	44.71%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	222.99%	44.49%	47.89%	39.70%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	257.62%	29.74%	28.16%	26.37%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	480.61%	74.23%	76.05%	66.07%
Earnings before Interest and Taxes (EBIT)	-65	-108	-170	-156	-157	11	-17	-36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-65	-109	-171	-154	-154	13	-15	-34
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	9.95	5.39	7.71	8.76	5.26	5.62	6.51
Price to Tangible Book Value (P/TBV)	0.00	9.95	5.39	7.71	9.78	5.51	5.85	6.77
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	42.07	9.46	9.13	6.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	11.36	175.20	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	8.80%	0.57%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	507.56	9.21	9.73	13.41
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	37.35	8.60	8.37	6.17
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	141.81	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	171.65	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	11.64	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	325.91	169.99	101.70
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	456.14
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.52	-1.14	-1.07	-1.04	-1.02	-0.64	-0.48	-0.51
Leverage Ratio	1.58	1.19	1.14	1.12	1.17	1.19	1.18	1.26
Compound Leverage Factor	1.57	1.14	1.10	1.12	1.17	1.19	1.18	1.26
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	398.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-298.41%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.22	38.11	21.87	35.95	15.04	19.25	16.55	11.80
Noncontrolling Interest Sharing Ratio	398.41%	38.72%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	2.70	7.37	8.68	10.46	4.38	5.16	4.34	3.30
Quick Ratio	2.61	7.22	8.39	10.16	4.15	4.32	3.58	2.84
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-63	-139	-106	-124	-40	-45	5.73
Operating Cash Flow to CapEx	-72,781.16%	-1,531.42%	-4,944.40%	-48,244.52%	-30,433.25%	41,478.57%	10,231.54%	10,194.05%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.13	0.64	0.55	0.76
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	26.46	15.93	13.44
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	3.72	3.41	6.58
Fixed Asset Turnover	0.00	0.00	0.00	0.00	11.20	98.03	225.97	606.36
Accounts Payable Turnover	0.00	0.00	0.00	0.00	8.38	9.62	11.14	36.80
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	13.80	22.91	27.16
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	98.21	106.99	55.44
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	43.55	37.95	32.76	9.92
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	-43.55	74.05	97.13	72.69
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	-16	-28	-7.96	-12	2.84	206	232	195
Invested Capital Turnover	0.00	0.00	0.00	0.00	-8.64	2.11	1.23	1.98
Increase / (Decrease) in Invested Capital	0.00	-12	20	-3.80	15	203	27	-38
Enterprise Value (EV)	227	2,472	981	2,082	1,439	1,893	2,261	2,613
Market Capitalization	153	2,779	1,214	2,406	1,622	2,083	2,467	2,856
Book Value per Share	($49.57)	$2.82	$2.05	$2.29	$1.34	$2.85	$3.12	$3.04
Tangible Book Value per Share	($49.57)	$2.82	$2.05	$2.29	$1.20	$2.72	$3.00	$2.92
Total Capital	30	279	225	312	185	396	439	438
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-46	-307	-233	-324	-182	-191	-206	-244
Capital Expenditures (CapEx)	0.07	5.29	3.20	0.28	0.42	0.01	0.13	0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-16	-36	-20	-22	-31	5.39	6.26	-12
Debt-free Net Working Capital (DFNWC)	30	271	214	301	152	196	213	231
Net Working Capital (NWC)	30	271	214	301	152	196	213	231
Net Nonoperating Expense (NNE)	19	28	43	51	48	-21	-32	11
Net Nonoperating Obligations (NNO)	-46	-307	-233	-324	-182	-191	-206	-244
Total Depreciation and Amortization (D&A)	0.03	-1.14	-1.43	2.53	3.02	2.32	1.27	2.14
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	-79.34%	2.45%	2.32%	-2.94%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	393.37%	89.02%	78.68%	54.62%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	393.37%	89.02%	78.68%	54.62%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	($2.30)	$2.64	$0.20	($0.60)
Adjusted Weighted Average Basic Shares Outstanding	1.81M	108.66M	111.09M	136.46M	68.58M	69.38M	70.06M	71.42M
Adjusted Diluted Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	($2.30)	$2.60	$0.20	($0.60)
Adjusted Weighted Average Diluted Shares Outstanding	1.81M	108.66M	111.09M	136.46M	68.58M	70.42M	71.92M	71.42M
Adjusted Basic & Diluted Earnings per Share	($35.85)	($3.49)	($2.99)	($2.61)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.81M	29.55M	54.05M	61.84M	138.21M	139.51M	141.23M	145.29M
Normalized Net Operating Profit after Tax (NOPAT)	-46	-76	-119	-110	-110	6.84	-18	-32
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-284.47%	3.11%	-6.53%	-7.54%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	-406.13%	5.01%	-6.16%	-8.54%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-3.54%	-0.07%	-0.70%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Kiniksa Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	719.64%	230.14%	50.19%	164.99%	-32.37%	34.76%	65.18%	51.99%	67.37%	46.93%
EBITDA Growth	257.06%	120.44%	56.25%	90.35%	-113.70%	-62.79%	-37.48%	242.31%	-12.92%	-685.00%
EBIT Growth	252.40%	118.93%	59.79%	93.57%	-118.19%	-64.19%	-52.46%	285.96%	15.27%	-793.02%
NOPAT Growth	1,136.71%	115.59%	51.99%	83.72%	-103.44%	-78.84%	-47.75%	108.99%	11.61%	-1,719.11%
Net Income Growth	833.67%	112.28%	51.33%	174.93%	-106.18%	465.73%	-44.29%	-126.10%	8.39%	-135.22%
EPS Growth	822.73%	113.21%	50.00%	172.41%	-106.29%	428.57%	-38.89%	-128.57%	10.00%	-129.73%
Operating Cash Flow Growth	317.66%	38.70%	88.42%	52.16%	-72.63%	137.36%	193.44%	238.07%	-113.16%	333.99%
Free Cash Flow Firm Growth	228.90%	-398.34%	-521.60%	-1,016.23%	-153.47%	86.87%	85.60%	104.93%	43.88%	192.55%
Invested Capital Growth	1,221.92%	7,147.57%	880.31%	1,382.82%	11.33%	13.10%	7.77%	-4.56%	4.50%	-16.20%
Revenue Q/Q Growth	267.55%	-37.58%	-21.88%	47.84%	-6.19%	24.38%	-4.24%	36.03%	3.30%	9.20%
EBITDA Q/Q Growth	354.12%	-84.63%	-235.76%	81.80%	-260.82%	141.74%	-601.60%	118.84%	-386.29%	-116.22%
EBIT Q/Q Growth	342.59%	-85.36%	-236.88%	86.77%	-585.96%	128.83%	-682.69%	116.14%	-412.54%	-135.79%
NOPAT Q/Q Growth	1,741.51%	-98.23%	-298.75%	71.83%	-246.45%	110.91%	-1,487.81%	101.71%	-3,506.65%	-99.82%
Net Income Q/Q Growth	1,221.53%	-98.01%	-375.05%	222.02%	-192.54%	282.15%	-170.15%	77.93%	-224.80%	29.98%
EPS Q/Q Growth	1,196.55%	-97.80%	-357.14%	216.67%	-195.24%	285.00%	-167.57%	76.00%	-200.00%	38.89%
Operating Cash Flow Q/Q Growth	893.11%	-118.66%	63.14%	12.28%	553.81%	-74.54%	-7.82%	29.62%	-143.27%	939.45%
Free Cash Flow Firm Q/Q Growth	377.66%	-474.10%	4.52%	-12.55%	86.70%	8.15%	-4.71%	138.52%	-251.48%	251.47%
Invested Capital Q/Q Growth	1,099.03%	12.14%	-1.43%	11.88%	-9.98%	13.93%	-6.08%	-0.92%	-1.44%	-8.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.34%	77.00%	68.30%	69.66%	60.63%	68.20%	60.70%	61.03%	55.96%	46.07%
EBITDA Margin	47.52%	11.70%	-20.33%	-2.50%	-9.63%	3.23%	-16.92%	2.34%	-6.50%	-12.86%
Operating Margin	46.82%	9.77%	-23.16%	-4.41%	-16.30%	0.10%	-20.71%	-0.11%	-8.61%	-15.75%
EBIT Margin	47.14%	11.05%	-19.37%	-1.73%	-12.68%	2.94%	-17.88%	2.12%	-6.42%	-13.86%
Profit (Net Income) Margin	226.05%	7.21%	-25.38%	20.95%	-20.66%	30.26%	-22.17%	-3.60%	-11.31%	-7.25%
Tax Burden Percent	479.50%	65.21%	131.03%	-1,208.39%	163.02%	1,030.08%	124.01%	-169.62%	176.27%	52.35%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	-379.50%	34.79%	0.00%	0.00%	0.00%	-930.08%	0.00%	269.62%	0.00%	0.00%
Return on Invested Capital (ROIC)	403.19%	13.47%	-34.32%	-7.17%	-14.65%	1.23%	-20.79%	0.28%	-11.09%	-21.84%
ROIC Less NNEP Spread (ROIC-NNEP)	402.42%	13.19%	-31.66%	-17.80%	-11.56%	-11.06%	-17.74%	2.31%	-8.30%	-23.90%
Return on Net Nonoperating Assets (RNNOA)	-269.76%	-8.46%	18.95%	10.18%	5.89%	5.26%	8.65%	-1.10%	4.19%	12.26%
Return on Equity (ROE)	133.43%	5.01%	-15.37%	3.01%	-8.77%	6.49%	-12.14%	-0.82%	-6.90%	-9.58%
Cash Return on Invested Capital (CROIC)	-194.88%	-38.56%	-8.63%	-5.20%	-17.67%	-20.35%	-17.64%	-4.03%	-13.20%	2.68%
Operating Return on Assets (OROA)	23.42%	7.03%	-13.59%	-1.40%	-6.69%	1.61%	-11.21%	1.40%	-4.75%	-10.60%
Return on Assets (ROA)	112.29%	4.58%	-17.80%	16.93%	-10.90%	16.59%	-13.90%	-2.38%	-8.37%	-5.55%
Return on Common Equity (ROCE)	133.43%	5.01%	-15.37%	3.01%	-8.77%	6.49%	-12.14%	-0.82%	-6.90%	-9.58%
Return on Equity Simple (ROE_SIMPLE)	37.13%	0.00%	50.32%	56.18%	-1.65%	0.00%	2.00%	-2.35%	-2.08%	0.00%
Net Operating Profit after Tax (NOPAT)	223	3.94	-7.84	-2.21	-7.65	0.83	-12	0.20	-6.76	-14
NOPAT Margin	224.49%	6.37%	-16.21%	-3.09%	-11.41%	1.00%	-14.50%	0.18%	-6.02%	-11.02%
Net Nonoperating Expense Percent (NNEP)	0.77%	0.28%	-2.66%	10.63%	-3.09%	12.29%	-3.05%	-2.03%	-2.79%	2.05%
Return On Investment Capital (ROIC_SIMPLE)	-	1.00%	-	-	-	0.19%	-	-	-	-3.08%
Cost of Revenue to Revenue	11.66%	23.00%	31.70%	30.34%	39.37%	31.80%	39.30%	38.97%	44.04%	53.93%
SG&A Expenses to Revenue	24.89%	43.98%	60.08%	40.82%	51.41%	44.05%	48.44%	39.03%	41.35%	33.08%
R&D to Revenue	16.63%	23.25%	31.38%	33.25%	25.51%	24.04%	32.98%	22.11%	23.22%	28.74%
Operating Expenses to Revenue	41.52%	67.23%	91.46%	74.07%	76.92%	68.10%	81.41%	61.14%	64.57%	61.82%
Earnings before Interest and Taxes (EBIT)	47	6.84	-9.36	-1.24	-8.50	2.45	-14	2.30	-7.20	-17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	47	7.24	-9.83	-1.79	-6.46	2.69	-14	2.55	-7.29	-16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.65	5.26	3.85	4.78	6.02	5.62	6.43	6.09	8.15	6.51
Price to Tangible Book Value (P/TBV)	4.88	5.51	4.03	5.00	6.29	5.85	6.69	6.33	8.47	6.77
Price to Revenue (P/Rev)	10.08	9.46	6.35	7.01	9.80	9.13	9.20	7.82	9.27	6.75
Price to Earnings (P/E)	12.51	11.36	7.65	8.51	0.00	175.20	320.87	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	7.99%	8.80%	13.08%	11.75%	0.00%	0.57%	0.31%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.64	9.21	6.48	7.87	10.96	9.73	11.73	11.23	15.65	13.41
Enterprise Value to Revenue (EV/Rev)	8.94	8.60	5.56	6.35	8.99	8.37	8.49	7.17	8.69	6.17
Enterprise Value to EBITDA (EV/EBITDA)	0.00	141.81	50.56	41.74	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	171.65	52.66	41.50	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	11.64	7.62	8.70	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	325.91	34.22	41.99	0.00	169.99	118.86	79.77	296.78	101.70
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	456.14
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.67	-0.64	-0.60	-0.57	-0.51	-0.48	-0.49	-0.48	-0.50	-0.51
Leverage Ratio	1.19	1.19	1.21	1.23	1.20	1.18	1.17	1.21	1.23	1.26
Compound Leverage Factor	1.19	1.19	1.21	1.23	1.20	1.18	1.17	1.21	1.23	1.26
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	13.79	19.22	16.47	15.90	18.27	16.67	18.60	14.64	17.88	11.91
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.28	5.16	6.33	5.18	4.79	4.34	4.21	3.57	3.24	3.30
Quick Ratio	3.75	4.32	5.33	4.42	3.82	3.58	3.57	2.84	2.59	2.84
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	53	-199	-190	-214	-28	-26	-27	11	-16	24
Operating Cash Flow to CapEx	193,915.63%	0.00%	-17,779.17%	-11,008.82%	106,162.50%	7,723.21%	4,746.43%	0.00%	0.00%	9,725.39%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.50	0.64	0.70	0.81	0.53	0.55	0.63	0.66	0.74	0.76
Accounts Receivable Turnover	24.62	26.46	12.82	17.30	35.03	15.93	25.77	15.03	27.51	13.44
Inventory Turnover	3.70	3.72	2.72	2.86	3.86	3.41	4.18	4.31	5.52	6.58
Fixed Asset Turnover	68.58	98.03	122.20	170.93	170.78	225.97	286.72	384.93	519.40	606.36
Accounts Payable Turnover	24.01	9.62	20.87	39.62	62.59	11.14	30.18	31.50	32.05	36.80
Days Sales Outstanding (DSO)	14.83	13.80	28.47	21.09	10.42	22.91	14.16	24.29	13.27	27.16
Days Inventory Outstanding (DIO)	98.61	98.21	134.26	127.50	94.50	106.99	87.30	84.76	66.17	55.44
Days Payable Outstanding (DPO)	15.20	37.95	17.49	9.21	5.83	32.76	12.09	11.59	11.39	9.92
Cash Conversion Cycle (CCC)	98.23	74.05	145.23	139.38	99.09	97.13	89.37	97.46	68.05	72.69
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	183	206	203	227	204	232	218	216	213	195
Invested Capital Turnover	1.80	2.11	2.12	2.32	1.28	1.23	1.43	1.53	1.84	1.98
Increase / (Decrease) in Invested Capital	169	203	182	211	21	27	16	-10	9.18	-38
Enterprise Value (EV)	1,583	1,893	1,314	1,783	2,237	2,261	2,562	2,430	3,337	2,613
Market Capitalization	1,784	2,083	1,501	1,968	2,438	2,467	2,776	2,649	3,561	2,856
Book Value per Share	$2.76	$2.85	$2.80	$2.94	$2.89	$3.12	$6.11	$3.07	$3.07	$3.04
Tangible Book Value per Share	$2.63	$2.72	$2.67	$2.82	$2.76	$3.00	$5.87	$2.95	$2.95	$2.92
Total Capital	384	396	390	412	405	439	432	435	437	438
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-201	-191	-187	-185	-201	-206	-214	-219	-224	-244
Capital Expenditures (CapEx)	0.03	-0.04	0.02	0.03	0.02	0.06	0.08	0.00	0.00	0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	5.39	7.42	14	1.56	6.26	-7.17	-2.03	-8.43	-12
Debt-free Net Working Capital (DFNWC)	185	196	195	199	203	213	206	217	215	231
Net Working Capital (NWC)	185	196	195	199	203	213	206	217	215	231
Net Nonoperating Expense (NNE)	-1.54	-0.52	4.43	-17	6.21	-24	6.12	4.11	5.93	-4.62
Net Nonoperating Obligations (NNO)	-201	-191	-187	-185	-201	-206	-214	-219	-224	-244
Total Depreciation and Amortization (D&A)	0.37	0.40	-0.47	-0.55	2.04	0.24	0.76	0.24	-0.09	1.22
Debt-free, Cash-free Net Working Capital to Revenue	-8.70%	2.45%	3.14%	4.83%	0.63%	2.32%	-2.38%	-0.60%	-2.20%	-2.94%
Debt-free Net Working Capital to Revenue	104.68%	89.02%	82.47%	70.71%	81.46%	78.68%	68.39%	63.95%	56.07%	54.62%
Net Working Capital to Revenue	104.68%	89.02%	82.47%	70.71%	81.46%	78.68%	68.39%	63.95%	56.07%	54.62%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.23	$0.06	($0.18)	$0.21	($0.20)	$0.37	($0.25)	($0.06)	($0.18)	($0.11)
Adjusted Weighted Average Basic Shares Outstanding	69.45M	69.38M	69.75M	69.92M	70.19M	70.06M	70.63M	71.00M	71.73M	71.42M
Adjusted Diluted Earnings per Share	$3.18	$0.07	($0.18)	$0.21	($0.20)	$0.37	($0.25)	($0.06)	($0.18)	($0.11)
Adjusted Weighted Average Diluted Shares Outstanding	70.55M	70.42M	69.75M	71.63M	70.19M	71.92M	70.63M	71.00M	71.73M	71.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	139.06M	139.51M	139.80M	140.33M	140.68M	141.23M	141.88M	142.49M	144.40M	145.29M
Normalized Net Operating Profit after Tax (NOPAT)	32	3.94	-7.84	-2.21	-7.65	0.06	-12	-0.08	-6.76	-14
Normalized NOPAT Margin	32.77%	6.37%	-16.21%	-3.09%	-11.41%	0.07%	-14.50%	-0.08%	-6.02%	-11.02%
Pre Tax Income Margin	47.14%	11.05%	-19.37%	-1.73%	-12.68%	2.94%	-17.88%	2.12%	-6.42%	-13.86%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Kiniksa Pharmaceuticals' Financials

When does Kiniksa Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Kiniksa Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Kiniksa Pharmaceuticals' net income changed over the last 7 years?

Kiniksa Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$43.19 million in 2024, falling from -$64.87 million in 2017. The previous period was $14.08 million in 2023.

What is Kiniksa Pharmaceuticals's operating income?

Kiniksa Pharmaceuticals's total operating income in 2024 was -$45.62 million, based on the following breakdown:

Total Gross Profit: $234.02 million
Total Operating Expenses: $279.63 million

How has Kiniksa Pharmaceuticals revenue changed over the last 7 years?

Over the last 7 years, Kiniksa Pharmaceuticals' total revenue changed from $0.00 in 2017 to $423.24 million in 2024, a change of 42,323,900,000.0%.

How much debt does Kiniksa Pharmaceuticals have?

Kiniksa Pharmaceuticals' total liabilities were at $142.12 million at the end of 2024, a 62.5% increase from 2023, and a 715.4% increase since 2017.

How much cash does Kiniksa Pharmaceuticals have?

In the past 7 years, Kiniksa Pharmaceuticals' cash and equivalents has ranged from $45.56 million in 2017 to $183.58 million in 2024, and is currently $183.58 million as of their latest financial filing in 2024.

How has Kiniksa Pharmaceuticals' book value per share changed over the last 7 years?

Over the last 7 years, Kiniksa Pharmaceuticals' book value per share changed from -49.57 in 2017 to 3.04 in 2024, a change of -106.1%.

Related Companies

This page (NASDAQ:KNSA) was last updated on 4/17/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals (KNSA) Financials

Frequently Asked Questions About Kiniksa Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals (KNSA) Financials

Annual Income Statements for Kiniksa Pharmaceuticals

Quarterly Income Statements for Kiniksa Pharmaceuticals

Annual Cash Flow Statements for Kiniksa Pharmaceuticals

Quarterly Cash Flow Statements for Kiniksa Pharmaceuticals

Annual Balance Sheets for Kiniksa Pharmaceuticals

Quarterly Balance Sheets for Kiniksa Pharmaceuticals

Annual Metrics and Ratios for Kiniksa Pharmaceuticals

Quarterly Metrics and Ratios for Kiniksa Pharmaceuticals

Frequently Asked Questions About Kiniksa Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools